Study S000733

Efficacy and Safety of Tirzepatide Versus Placebo or Lisdexamfetamine Dimesylate for Binge-Eating Disorder: A Randomized Clinical Trial

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT06847399
Acronym: LIBERATE
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: QUADRUPLE
Status: RECRUITING
Enrollment: 105
Start: 2025-09-17
Primary completion: 2027-12-01
Lead sponsor: Johns Hopkins University
Conditions: Obesity and Overweight; Binge Eating Disorder
Interventions: DRUG:Tirzepatide; DRUG:Lisdexamfetamine Dimesylate; BEHAVIORAL:Guided self-help cognitive behavioral therapy; DRUG:Placebo (oral); DRUG:Placebo (injection)
Results posted: FALSE

Registered primary outcomes

Percent initial weight loss [Baseline to 52 weeks]
Change in the Number of Binge-eating episodes [Baseline to 52 weeks]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.